A once-thought silent mutation in a major plasma protein inhibitor, alpha-1-antitrypsin, confers added risk for large artery ischemic stroke. RELENT partners at HelmholtzZentrum München, Therese Dau (shared first author) and Dieter E. Jenne are co-authors on this article that was published in PNAS in April 2017.